KR920016423A - 루코트리엔 길항제로서의 퀴놀린-함유 케토산 - Google Patents

루코트리엔 길항제로서의 퀴놀린-함유 케토산 Download PDF

Info

Publication number
KR920016423A
KR920016423A KR1019920002536A KR920002536A KR920016423A KR 920016423 A KR920016423 A KR 920016423A KR 1019920002536 A KR1019920002536 A KR 1019920002536A KR 920002536 A KR920002536 A KR 920002536A KR 920016423 A KR920016423 A KR 920016423A
Authority
KR
South Korea
Prior art keywords
mammal
compound
effective amount
antagonists
administering
Prior art date
Application number
KR1019920002536A
Other languages
English (en)
Inventor
엘. 벨리 미셀
Original Assignee
제임스 에프. 노턴
머크 프로스트 캐나다 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제임스 에프. 노턴, 머크 프로스트 캐나다 인코포레이티드 filed Critical 제임스 에프. 노턴
Publication of KR920016423A publication Critical patent/KR920016423A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음

Description

루코트리엔 길항제로서의 퀴놀린 함유케토산
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 일반식(Ⅰ)의 화합물 및 약제학적으로 허용되는 이의 염.
    상기식에서, R1및 R2는 각각 독립적으로 H또는 저급 알킬이거나, 동일한 탄소원자에 결합되어 탄소수 3내지 6의 환을 형성하며, R3는 C1-C3알킬이고, R4는 C1 또는Br 이며, R5H, C1또는 Br 이고 X 는 H 또는 C1이며, n은 1내지4 이다
  2. 제1항에 있어서, 일반식(Ⅰa)의 화합물,
  3. 제1항에 있어서, 치환체가 다음과 같은 화합물.
  4. 나트륨 3-((1(S)-(3-(2-(7-클로로-2- 퀴놀리닐) 에테닐) 페닐)-3-(2 -아세틸페닐) 프로필) 티오)-2(S)- 메틸프로파노에이트.
  5. 치료학적 유효량의 제1항의 화합물 및 약제학적으로 허용되는 담체를 포함하는 약제학적 조성물.
  6. 제5항에 있어서, 비스테로이드성 소염제, 말초신경 진통제, 사이클옥시게나제 어제제, 류코트리엔 길항제, 류코트리엔 생합성 억제제, H1-또는 H2-수용체 길항제,항히스타민제, 프로스타클란딘 길항제 및 ACE길항제로 이루어지는 그룹중에서 선택된 제2활성 성분 유효량을 포함하는 약제학적 조성물.
  7. 제6항에 있어서, 제1항의화합물 대 제2황성 성분의 중량비가 약 1000 :1 내지 1:1000 인 약제학적 조성물.
  8. 포유동물에게 유효량의 제1항의 하합물을 투여함을 포함하여, 포유동물에 있어서의 SRS-A 또는 류코트리엔의 합성, 작용 및 방출을 예방하는 방법.
  9. 천식치료를 필요로 하는 포유동물에게 치료학적 유효량의 제1항의 화합물을 투여함을 포함하여 포유동물의 천식을 치료하는 방법.
  10. 눈의 염증 질환 치료를 필요로 하는 포유동물에게 치료학적 유효량의 제1하의 화합물을 투여함을 포함하여 포유동물의 눈의 염증질환을 치료하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920002536A 1991-02-21 1992-02-20 루코트리엔 길항제로서의 퀴놀린-함유 케토산 KR920016423A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65893191A 1991-02-21 1991-02-21
US07/658,931 1991-02-21

Publications (1)

Publication Number Publication Date
KR920016423A true KR920016423A (ko) 1992-09-24

Family

ID=24643302

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920002536A KR920016423A (ko) 1991-02-21 1992-02-20 루코트리엔 길항제로서의 퀴놀린-함유 케토산

Country Status (17)

Country Link
EP (1) EP0500360B1 (ko)
JP (1) JPH0788361B2 (ko)
KR (1) KR920016423A (ko)
CN (1) CN1065062A (ko)
AT (1) ATE154801T1 (ko)
AU (1) AU648385B2 (ko)
CA (1) CA2061675C (ko)
CS (1) CS47192A3 (ko)
DE (1) DE69220517T2 (ko)
ES (1) ES2104821T3 (ko)
FI (1) FI920734A (ko)
HU (1) HU9200552D0 (ko)
IE (1) IE920499A1 (ko)
IL (1) IL100985A0 (ko)
MX (1) MX9200714A (ko)
NO (1) NO920681L (ko)
ZA (1) ZA921232B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
GB9216768D0 (en) * 1992-08-07 1992-09-23 Leo Pharm Prod Ltd Chemical compounds
EP0830133A1 (en) * 1995-04-28 1998-03-25 Takeda Chemical Industries, Ltd. Therapeutic composition for arthritis
AU3868497A (en) * 1996-08-26 1998-03-19 Yamanouchi Pharmaceutical Co., Ltd. Benzenesulfone compounds and salts thereof
BR9906772A (pt) * 1998-07-14 2000-09-26 Alcon Lab Inc Uso de ácido 11-(3-dimetilamino-propilideno)-6,11diidrodibenz[b,e]o xepin-2-acético para a fabricação de um medicamento para tratamento de desordens inflamatórias oftálmicas não-alérgicas e para prevenção de neovascularização ocular
MXPA06012220A (es) * 2004-04-21 2007-07-18 Teva Pharma Procesos para preparar sodio de montelukast.
ITMI20050247A1 (it) * 2005-02-18 2006-08-19 Chemi Spa Processo per la preparazione di montelukast
WO2006131782A1 (en) * 2005-06-07 2006-12-14 Glade Organics Private Limited Process for the manufacture of methyl-2-(3-(2-(7-chloro-2-quinolinyl-ethenyl)-phenyl)-3-oxopropyl) benzoate
CA2608369A1 (en) 2005-07-05 2007-01-11 Teva Pharmaceutical Industries Ltd. Purification of montelukast
CN101356157B (zh) * 2005-11-18 2011-07-06 斯索恩有限公司 制备孟鲁司特及其中间体的方法
AR056815A1 (es) * 2005-11-18 2007-10-24 Synthon Bv PROCESO PARA PREPARAR MONTELUKAST, INTERMEDIARIOS DEL MISMO Y SUS SALES DE ADICIoN Y PROCEDIMIENTO DE PURIFICACIoN DE ÉSTOS Y DE MONTELUKAST
NZ575552A (en) * 2006-09-15 2012-02-24 Cipla Ltd Process for the preparation of montelukast, and intermediates therefor
ES2320077B1 (es) 2007-07-31 2010-02-26 Moehs Iberica, S.L. Proceso de preparacion de un antagonista de leucotrienos y de un intermedio del mismo.
CN101851196B (zh) * 2010-05-28 2011-07-27 中国科学院昆明植物研究所 2-(1h)喹啉酮衍生物,其药物组合物及其制备方法和用途
CA2842881A1 (en) * 2011-07-26 2013-04-11 Rajendrasinh RATHOD Cysteinyl leukotriene antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE59889B1 (en) * 1986-02-14 1994-04-20 Merck Frosst Canada Inc 2-substituted quinoline dioic acids
IL88433A0 (en) * 1987-11-25 1989-06-30 Merck Frosst Canada Inc Diarylstyrylquinoline diacids and pharmaceutical compositions containing them
EP0349062A1 (en) * 1988-06-27 1990-01-03 Merck Frosst Canada Inc. Quinoline ether alkanoic acid
NZ233752A (en) * 1989-05-24 1993-05-26 Merck Frosst Canada Inc Substituted quinoline derivatives, preparation and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
CA2061675C (en) 2002-12-17
FI920734A0 (fi) 1992-02-20
NO920681D0 (no) 1992-02-20
IE920499A1 (en) 1992-08-26
IL100985A0 (en) 1992-11-15
ES2104821T3 (es) 1997-10-16
HU9200552D0 (en) 1992-05-28
AU1111992A (en) 1992-08-27
EP0500360B1 (en) 1997-06-25
ZA921232B (en) 1992-10-28
CN1065062A (zh) 1992-10-07
FI920734A (fi) 1992-08-22
EP0500360A1 (en) 1992-08-26
JPH0525135A (ja) 1993-02-02
CS47192A3 (en) 1992-10-14
ATE154801T1 (de) 1997-07-15
CA2061675A1 (en) 1992-08-22
AU648385B2 (en) 1994-04-21
JPH0788361B2 (ja) 1995-09-27
DE69220517D1 (de) 1997-07-31
MX9200714A (es) 1992-10-01
NO920681L (no) 1992-08-24
DE69220517T2 (de) 1997-12-18

Similar Documents

Publication Publication Date Title
KR920016423A (ko) 루코트리엔 길항제로서의 퀴놀린-함유 케토산
KR920008006A (ko) 류코트리엔 길항제로서의 불포화 하이드록시 알킬퀴놀린산
PT95389A (pt) Processo para a preparacao de novos derivados pirazolicos com accao anti-inflamatoria
KR880007460A (ko) 3-헤테로-치환된-n-벤질-인돌
KR950702982A (ko) 치환된 티아졸리딘디온 유도체(Substituted Thiazolidinedione Derivatives)
KR910004600A (ko) 류코트리엔의 생합성 억제제로서의 (퀴놀린-2-일메톡시)인돌
ES2137169T3 (es) Nuevos derivados de tiazolilbenzofurano, procedimientos para su preparacion y composicion farmaceutica que los contiene.
KR970015578A (ko) 아릴알킬 디아진온
KR900018035A (ko) 디아릴스티릴퀴놀린 이산
KR900003170A (ko) 신규 화합물
KR930006014A (ko) 삼환식 복소환식 화합물
KR970706265A (ko) 아졸 유도체(Azole derivative)
KR870003991A (ko) 치환된 벤젠 유도체의 제조방법
KR930701415A (ko) 약학적으로 활성인 벤조퀴나졸린 화합물
KR890008104A (ko) 디아릴스티릴퀴놀린 이산
KR880003920A (ko) 피리다지논 유도체
KR940005558A (ko) 옥심 유도체
KR920008005A (ko) 류코트리엔 길항제로서의 하이드록시 알킬퀴놀린 에테르 산
KR930021638A (ko) 이미다조피리딘
NO178025C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive (benzhydryloksyetylpiperidyl)alifatiske syrederivater
KR940005621A (ko) 벤조[b]티오펜-3-일-피페라진. 이의 제조방법 및 약제로서 이의 용도
KR900006316A (ko) 벤조 헤테로 고리화합물 및 그 제조방법
KR927003564A (ko) 크로몬 유도체 및 이 화합물을 유효성분으로 하는 아르도스 리덕타제 저해제
KR880012520A (ko) 류코트리엔 길항제
KR890009890A (ko) 하이드록시 피리미딘의 아실 유도체

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid